“[T]The composition of a new panel with the addition of new judges that changed the outcome of the appeals court is beyond the powers of the court of appeals. – Overview of Law Professor and Civil Proceeding Scholar
Yellow traffic sign with wrong words on white background
Novartis Pharmaceuticals, Inc. to the U.S. Supreme Court this week asking a judge to consider whether the U.S. Court of Appeals for the Federal Circuit (CAFC) should have been allowed to reverse the decisions of three previous judges. Many supporters expressed their opinions on the petition. A panel of various judges invalidated Novartis’ patent for a dosing regimen for the multiple sclerosis drug Gilenya.
In January of this year, Novartis fulfilled its September 2022 promise to appeal to the Supreme Court the CAFC’s June 2022 decision that invalidated the CAFC’s U.S. Patent No. 9,187,405 in September 2022.
The two questions posed in the petition are:
- 28 USC § 46 and the principles of sound administration of justice require that the Court of Appeals add new judges to form a new panel, after the original three-judge panel has already decided the case and delivered its verdict. Whether redetermination of the case is prevented.
2. Whether 35 USC § 112 should be construed consistent with plain text requiring the patent specification to include a “written description of the invention” in a form understandable to “a person skilled in the art,” or the Court of Appeals Appropriate reading of the heightened requirements that allow de novo examination to consider the specification unsuitable, and to replace the point of view of those skilled in the art.
In the original CAFC decision, Chief Justice Moore opposed the majority decision to preserve the patent. At the hearing, Moore crafted an opinion overriding his January decision, which Judge Lynn dissented.
In a second CAFC decision, the panel majority noted that “there is a proper written explanation of a negative claim limitation if the specification explains the reasons for excluding the relevant one.” bottom. [element]Citing a 2012 Federal Circuit decision, by court dominate Santarus, Inc. v. Par Pharmaceuticals, Inc. Chief Justice Moore, writing that “silence is generally not disclosure,” reiterated a point she raised in an earlier dissenting opinion.
In the petition, Novartis emphasized that it is currently “only in the Ninth and Federal Circuits.” [that] Decisions already made can be overturned by adding new judges for a ‘panel’ review without review by the full court or change of mind by a panel judge. “
On February 21, three Amici joined to support Novartis.
Professor of Intellectual Property
A group of intellectual property law professors, including Adam Mossoff, Kristen Osenga, Emily Michiko Morris, and four others, focused on the substantive implications of the Federal Circuit’s decision to reverse an earlier panel hearing, stating: explained. A flexible approach to written explanations advocated by this court and the Supreme Court for the Federal Circuit. “Patentees must now indicate that claim limitations not set forth in every word of the specification must be understood to ‘always’ or ‘necessarily’ be present by those skilled in the art.” The panel’s ruling was too rigid, the professors added.
Moreover, the panel did not stay the fact-findings of the district court and the four experts in violation of the Fed. R. Civ. It precedes P. 52(a)(6) and the CAFC itself, Brief said.
Law professor and civil litigation scholar
The following Amicus brief was filed by a law professor and civil litigation scholar focusing on the procedural flaws in this case. The brief called the circumstances of the case “amazing” and said it was “legally unnecessary” to add a new judge to form the second panel. explained.
“Under 28 USC § 46(d), the two judges remaining on the first panel constituted a quorum with full authority to decide petitions for rehearing of the panel. , the formation of a new panel with the addition of new judges that changed the outcome of the appeal was beyond the powers of the Court of Appeals.”
The Opinion called the results of the Second Committee’s decision “amazing,” “unauthorized,” and “one-sided,” with “more losing parties being the most inefficient, cumbersome, and non-competitive.” It would encourage them to file a productive kind of petition for rehearing, simply rehashing arguments the panel has already dismissed.”
retired circuit judge
Finally, a number of retired U.S. Circuit Judges have argued that the Federal Circuit’s and Ninth Circuit’s approach to reconstituting divided panels with new Judges after a Judge’s retirement is “not a matter of law or sound judicial practice.” I submitted a written opinion claiming that it cannot be matched with. The judge said the Federal Circuit’s system was plainly wrong and that “a panel rehearing should not be a losing side’s starting over.” It’s believed to be the same panel that did it, Brief said.
The Federal Circuit could not explain why it replaced the retired judge and overturned the decision, but the Ninth Circuit said the court “has the right to withdraw or amend its opinion at any time before issuance of the power of attorney.” He justified the practice on the premise that he has authority. But the judge said this approach “overstates the meaning of the period between judgments and orders” and meant that the published opinion was “only halfway through the final decision process.” . Like a law professor and civil litigator, the retired judge said a quorum of her two remaining judges on the retired panel should retry the case. rice field.
HEC Pharmaceuticals has not filed an answer with the court.
Image Source:Deposit Photos
Image ID: 637848838
Author: thaneeh.gmail.com
